
About Bandaram Pharma Packtech
Bandaram Pharma Packtech is a publicly listed company based in Bengaluru (India) founded in 2022. Pharmaceutical packaging solutions are provided by Bandaram Pharma Packtech. Its Indian entity Bandaram Pharma Packtech Limited reported revenue of ₹62.94 Cr. Bandaram Pharma Packtech offers products and services including Investment Services. Its focus areas include Biopharma Outsourcing, Logistics & Supply Chain and Packaging. Its competitors include SCHOTT Poonawalla, Ideal Cures and Natural Capsules.
Company details
Bandaram Pharma Packtech was established in 2022 and is based in Bengaluru, India. Operations focus on the pharmaceutical sector, where packaging solutions are developed and supplied. Services include design, manufacturing, and distribution of packaging materials tailored for pharmaceutical products. The company serves clients within India, emphasizing compliance with industry standards for safety and efficiency in drug containment and transport.
- Headquarters Bengaluru, India
- Stage Public
- SectorsHealthcare
- Website bandaram.com
- Legal Name Bandaram Pharma Packtech Limited
- Market Cap₹32.94 Cr
BANDARAM · BSE
- Share Price₹18.59
+1.42% today
- Revenue₹62.92 Cr
FY 2025-26 · +70.2% YoY
- EBITDA₹2.90 Cr
Margin 4.6%
- Net Profit₹0.45 Cr
FY 2025-26 · -54.1% YoY
- P/E (TTM)132.4x
P/B 1.2x
- ROE1.4%
ROCE 4.8%
- Debt / Equity1.04
Interest cover 78.2x
Associated legal entities of Bandaram Pharma Packtech
Bandaram Pharma Packtech operates through Bandaram Pharma Packtech Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Bandaram Pharma Packtech Limited Listed CIN L93090KA1993PLC159827 | Active | 05 Aug 1993 | Bangalore, Karnataka | ₹62.9 Cr | 9 | View details |
Products & Services of Bandaram Pharma Packtech
Bandaram Pharma Packtech offers a comprehensive portfolio of products and services, including Investment Services.
Managing investments in subsidiaries for long-term growth and value
Board of directors of Bandaram Pharma Packtech Limited (Bandaram Pharma Packtech)
Bandaram Pharma Packtech Limited is the primary company behind Bandaram Pharma Packtech. The board of Bandaram Pharma Packtech Limited currently have 7 directors; the longest-serving is Bhandaram Sathyavathi, appointed in 2022. 26 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Bhandaram Sathyavathi DIN 07638353 | Director | 07 Mar 2022 | 4 yrs 8 mo | Bandaram Pharma Packtech Limited |
| Bhandaram Premsai Reddy DIN 07170946 | Director | 07 Mar 2022 | 4 yrs 8 mo | Bandaram Pharma Packtech Limited |
| Suryaprakasa Rao Bommisetti DIN 08089189 | Director | 07 Mar 2022 | 4 yrs 8 mo | Bandaram Pharma Packtech Limited |
| Deepak Bandaram DIN 07074102 | Managing Director | 07 Feb 2023 | 3 yrs 9 mo | Bandaram Pharma Packtech Limited |
| Suman Mallu DIN 10302888 | Director | 01 Sep 2023 | 3 yrs 2 mo | Bandaram Pharma Packtech Limited |
| Mounika Pammi DIN 11111376 | Director | 20 Jun 2025 | 1 yr 4 mo | Bandaram Pharma Packtech Limited |
| Eswar Reddy Putturu DIN 11510880 | Director | 30 Jan 2026 | 9 mo | Bandaram Pharma Packtech Limited |
IPO & Listings of Bandaram Pharma Packtech
Bandaram Pharma Packtech is a publicly listed company on the BSE with ticker symbol BANDARAM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Aug 1994
- Listed onBSE: 524602
- Listed entityBandaram Pharma Packtech Limited
- Exchange sectorHealth technology
- ISININE875N01036
- Share price₹19.10 (+2.96% on the day) · 2026-10-14
- Volume (last session)276
Financials of Bandaram Pharma Packtech
Exchange-reported figures of Bandaram Pharma Packtech Limited, the listed company behind Bandaram Pharma Packtech (BSE: BANDARAM).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 62.92 | 36.96 | 34.08 | 18.73 |
| Revenue growth | +70.2% | +8.5% | +82.0% | - |
| EBITDA | 2.90 | 2.81 | 2.82 | 1.15 |
| EBITDA margin | +4.6% | +7.6% | +8.3% | +6.1% |
| Profit before tax | 0.44 | 1.30 | 1.19 | 0.32 |
| Net profit | 0.45 | 0.98 | 0.95 | 0.13 |
| Net profit margin | +0.7% | +2.7% | +2.8% | +0.7% |
| EPS (₹) | 0.25 | 0.83 | 0.79 | 0.47 |
| Balance sheet | ||||
| Total assets | 55.31 | 32.98 | 27.27 | 19.34 |
| Net worth | 26.78 | 12.65 | 12.28 | 3.08 |
| Total debt | 23.95 | 17.15 | 12.20 | 14.20 |
| Cash & bank | 0.72 | 0.12 | 0.04 | 0.16 |
| Net working capital | 36.56 | 25.02 | 21.35 | 14.27 |
| Cash flow | ||||
| Cash from operations | (4.92) | (4.93) | (4.13) | (1.10) |
| Cash from investing | 0.00 | (0.08) | (1.58) | (5.30) |
| Cash from financing | 5.53 | 5.09 | 5.59 | 4.47 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21.45 | 23.95 | 26.26 | 14.84 | 13.72 | 8.10 | 8.49 | 10.00 |
| Revenue growth (YoY) | +56.3% | +195.7% | +209.3% | +48.4% | +93.0% | -28.8% | - | - |
| Other income | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.09 | 0.00 |
| EBITDA | 1.16 | 1.54 | 0.82 | 1.00 | 0.45 | 0.63 | 0.54 | 0.66 |
| EBITDA margin | +5.4% | +6.4% | +3.1% | +6.7% | +3.3% | +7.8% | +6.4% | +6.6% |
| Depreciation | 0.25 | 0.20 | 0.25 | 0.14 | 0.14 | 0.13 | 0.53 | 0.15 |
| Interest | 0.48 | 0.42 | 0.46 | 0.33 | 0.25 | 0.46 | (0.10) | 0.24 |
| Profit before tax | 0.43 | 0.92 | 0.12 | 0.53 | 0.07 | 0.04 | 0.20 | 0.27 |
| Tax | 0.24 | 0.24 | 0.03 | 0.18 | 0.02 | 0.01 | 0.05 | 0.28 |
| Net profit | 0.19 | 0.68 | 0.09 | 0.35 | 0.05 | 0.03 | 0.15 | (0.01) |
| EPS (₹) | (0.12) | 0.11 | 0.05 | 0.11 | 0.03 | 0.02 | 0.13 | (0.01) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2017-18 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 10.96 | 12.23 | 14.84 | 10.09 | 0.00 | 0.00 | 0.00 |
| Revenue growth | -10.4% | -17.6% | +47.1% | - | - | - | - |
| EBITDA | (1.17) | 0.09 | 0.16 | 0.27 | (0.01) | (0.01) | (1.12) |
| EBITDA margin | -10.7% | +0.7% | +1.1% | +2.7% | - | - | - |
| Profit before tax | (1.16) | 0.17 | 0.17 | 0.27 | (0.01) | (0.03) | (1.16) |
| Net profit | (1.16) | 0.12 | 0.13 | 0.20 | (0.01) | (0.03) | (1.16) |
| Net profit margin | -10.6% | +1.0% | +0.9% | +2.0% | - | - | - |
| EPS (₹) | (0.64) | 0.12 | 0.11 | 0.68 | (0.03) | (0.14) | 0.00 |
| Balance sheet | |||||||
| Total assets | 27.40 | 15.59 | 12.22 | 7.48 | 2.99 | 0.10 | 0.39 |
| Net worth | 22.88 | 12.10 | 12.20 | 3.07 | 2.99 | (2.32) | (1.78) |
| Total debt | 4.51 | 3.49 | 0.02 | 4.41 | 0.00 | 1.45 | 1.20 |
| Cash & bank | 0.26 | 0.02 | 0.04 | 0.09 | 2.08 | 0.00 | 0.00 |
| Net working capital | 5.50 | 6.49 | 8.30 | 4.95 | 2.99 | (0.39) | (0.18) |
| Cash flow | |||||||
| Cash from operations | 1.21 | (3.25) | (3.26) | (3.87) | 2.92 | 0.00 | (0.98) |
| Cash from investing | (2.00) | 0.00 | (1.40) | (2.53) | (1.55) | 0.00 | 0.42 |
| Cash from financing | 1.03 | 3.23 | 4.61 | 4.40 | 0.72 | 0.00 | 0.00 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.37 | 2.99 | 8.20 | 1.68 | 0.33 | 0.76 | 3.71 | 2.63 |
| Revenue growth (YoY) | +618.2% | +293.4% | +121.0% | -36.1% | -89.6% | -72.1% | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.09 | 0.00 |
| Total expenses | 2.78 | 3.34 | 8.53 | 1.89 | 0.68 | 1.03 | 3.75 | 2.58 |
| EBITDA | (0.41) | (0.35) | (0.33) | (0.21) | (0.35) | (0.27) | (0.04) | 0.05 |
| EBITDA margin | -17.3% | -11.7% | -4.0% | -12.5% | -106.1% | -35.5% | -1.1% | +1.9% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.41) | (0.35) | (0.33) | (0.21) | (0.34) | (0.27) | 0.05 | 0.05 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21.45 | 23.95 | 26.26 | 14.84 | 13.72 | 8.10 | 8.49 | 10.00 |
| Revenue growth (YoY) | +56.3% | +195.7% | +209.3% | +48.4% | +93.0% | -28.8% | - | - |
| Other income | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.09 | 0.00 |
| EBITDA | 1.16 | 1.54 | 0.82 | 1.00 | 0.45 | 0.63 | 0.54 | 0.66 |
| EBITDA margin | +5.4% | +6.4% | +3.1% | +6.7% | +3.3% | +7.8% | +6.4% | +6.6% |
| Depreciation | 0.25 | 0.20 | 0.25 | 0.14 | 0.14 | 0.13 | 0.53 | 0.15 |
| Interest | 0.48 | 0.42 | 0.46 | 0.33 | 0.25 | 0.46 | (0.10) | 0.24 |
| Profit before tax | 0.43 | 0.92 | 0.12 | 0.53 | 0.07 | 0.04 | 0.20 | 0.27 |
| Tax | 0.24 | 0.24 | 0.03 | 0.18 | 0.02 | 0.01 | 0.05 | 0.28 |
| Net profit | 0.19 | 0.68 | 0.09 | 0.35 | 0.05 | 0.03 | 0.15 | (0.01) |
| EPS (₹) | (0.12) | 0.11 | 0.05 | 0.11 | 0.03 | 0.02 | 0.13 | (0.01) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 62.92 | 36.96 | 34.08 | 18.73 |
| Revenue growth | +70.2% | +8.5% | +82.0% | - |
| Other income | 0.02 | 0.09 | 0.03 | 0.19 |
| Total expenses | 60.02 | 34.15 | 31.26 | 17.58 |
| Employee cost | 0.00 | 2.96 | 2.33 | 0.64 |
| EBITDA | 2.90 | 2.81 | 2.82 | 1.15 |
| EBITDA margin | +4.6% | +7.6% | +8.3% | +6.1% |
| Depreciation | 0.97 | 0.61 | 0.73 | 0.59 |
| Interest | 1.51 | 0.99 | 0.93 | 0.43 |
| Profit before tax | 0.44 | 1.30 | 1.19 | 0.32 |
| Tax | (0.01) | 0.32 | 0.24 | 0.07 |
| Net profit | 0.45 | 0.98 | 0.95 | 0.13 |
| Net profit margin | +0.7% | +2.7% | +2.8% | +0.7% |
| EPS (₹) | 0.25 | 0.83 | 0.79 | 0.47 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 17.97 | 12.00 | 12.00 | 3.00 |
| Reserves & surplus | 8.81 | 0.65 | 0.28 | 0.08 |
| Shareholders' funds (net worth) | 26.78 | 12.65 | 12.28 | 3.08 |
| Minority interest | 4.58 | 3.17 | 2.79 | 2.05 |
| Secured loans | 14.92 | 10.52 | 1.78 | 1.97 |
| Unsecured loans | 9.03 | 6.63 | 10.42 | 12.23 |
| Total debt | 23.95 | 17.15 | 12.20 | 14.20 |
| Total liabilities | 55.31 | 32.98 | 27.27 | 19.34 |
| Assets | ||||
| Gross block | 15.22 | 3.95 | 5.91 | 5.03 |
| Net block | 15.22 | 3.95 | 4.48 | 5.03 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 1.40 | 1.40 | 0.00 |
| Inventories | 12.94 | 8.51 | 6.47 | 2.71 |
| Sundry debtors | 31.35 | 18.76 | 14.52 | 6.62 |
| Cash & bank balances | 0.72 | 0.12 | 0.04 | 0.16 |
| Loans & advances | 11.98 | 3.50 | 5.03 | 5.57 |
| Total current assets | 56.99 | 30.89 | 26.06 | 15.06 |
| Total current liabilities | 20.43 | 5.87 | 4.71 | 0.79 |
| Net working capital | 36.56 | 25.02 | 21.35 | 14.27 |
| Total assets | 55.31 | 32.98 | 27.27 | 19.34 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 0.12 | 0.04 | 0.16 | 2.09 |
| Net cash from operating activities | (4.92) | (4.93) | (4.13) | (1.10) |
| Net cash from investing activities | 0.00 | (0.08) | (1.58) | (5.30) |
| Net cash from financing activities | 5.53 | 5.09 | 5.59 | 4.47 |
| Net change in cash | 0.60 | 0.08 | (0.11) | (1.93) |
| Closing cash | 0.72 | 0.12 | 0.04 | 0.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | +70.2% | +8.5% | +82.0% | - |
| EBITDA growth | +3.2% | -0.4% | +145.2% | - |
| PBT growth | -66.2% | +9.2% | +271.9% | +9997.0% |
| Net income growth | -54.1% | +3.2% | +630.8% | - |
| Revenue CAGR (3Y) | +49.8% | - | - | - |
| EBITDA CAGR (3Y) | +36.1% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +0.5% | +2.7% | +2.8% | +1.3% |
| Return on capital employed | +4.8% | +8.5% | +10.2% | +4.4% |
| Return on net worth | +1.4% | +7.9% | +12.4% | +8.4% |
| Debt / equity | 1.04 | 1.18 | 1.72 | 4.61 |
| Long-term debt / equity | 0.48 | 0.55 | 0.80 | 2.48 |
| Interest cover | 78.24 | 45.00 | 44.50 | 76.79 |
| Efficiency & per share | ||||
| Fixed asset turnover | 6.56 | 7.50 | 6.23 | 3.72 |
| Inventory turnover | 5.87 | 4.93 | 7.42 | 6.91 |
| Debtors turnover | 2.51 | 2.22 | 3.22 | 2.83 |
| EPS (₹) | 0.16 | 0.83 | 0.79 | 0.47 |
| Dividend per share (₹) | 0.00 | 0.10 | 0.10 | 0.10 |
| Book value per share (₹) | 14.90 | 10.54 | 10.23 | 10.28 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.37 | 2.99 | 8.20 | 1.68 | 0.33 | 0.76 | 3.71 | 2.63 |
| Revenue growth (YoY) | +618.2% | +293.4% | +121.0% | -36.1% | -89.6% | -72.1% | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.09 | 0.00 |
| Total expenses | 2.78 | 3.34 | 8.53 | 1.89 | 0.68 | 1.03 | 3.75 | 2.58 |
| EBITDA | (0.41) | (0.35) | (0.33) | (0.21) | (0.35) | (0.27) | (0.04) | 0.05 |
| EBITDA margin | -17.3% | -11.7% | -4.0% | -12.5% | -106.1% | -35.5% | -1.1% | +1.9% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.41) | (0.35) | (0.33) | (0.21) | (0.34) | (0.27) | 0.05 | 0.05 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2017-18 |
|---|---|---|---|---|---|---|---|
| Revenue | 10.96 | 12.23 | 14.84 | 10.09 | 0.00 | 0.00 | 0.00 |
| Revenue growth | -10.4% | -17.6% | +47.1% | - | - | - | - |
| Other income | 0.01 | 0.09 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 12.13 | 12.14 | 14.68 | 9.82 | 0.01 | 0.01 | 1.12 |
| Employee cost | 0.00 | 1.10 | 1.14 | 0.08 | 0.00 | 0.00 | 0.37 |
| EBITDA | (1.17) | 0.09 | 0.16 | 0.27 | (0.01) | (0.01) | (1.12) |
| EBITDA margin | -10.7% | +0.7% | +1.1% | +2.7% | - | - | - |
| Depreciation | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 | 0.02 | 0.03 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Profit before tax | (1.16) | 0.17 | 0.17 | 0.27 | (0.01) | (0.03) | (1.16) |
| Tax | 0.00 | 0.05 | 0.04 | 0.07 | 0.00 | 0.00 | 0.00 |
| Net profit | (1.16) | 0.12 | 0.13 | 0.20 | (0.01) | (0.03) | (1.16) |
| Net profit margin | -10.6% | +1.0% | +0.9% | +2.0% | - | - | - |
| EPS (₹) | (0.64) | 0.12 | 0.11 | 0.68 | (0.03) | (0.14) | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2017-18 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 17.97 | 12.00 | 12.00 | 3.00 | 3.00 | 2.28 | 2.28 |
| Reserves & surplus | 4.91 | 0.10 | 0.20 | 0.07 | (0.01) | (4.60) | (4.06) |
| Shareholders' funds (net worth) | 22.88 | 12.10 | 12.20 | 3.07 | 2.99 | (2.32) | (1.78) |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 4.51 | 3.49 | 0.02 | 4.41 | 0.00 | 1.45 | 1.20 |
| Total debt | 4.51 | 3.49 | 0.02 | 4.41 | 0.00 | 1.45 | 1.20 |
| Total liabilities | 27.40 | 15.59 | 12.22 | 7.48 | 2.99 | 0.10 | 0.39 |
| Assets | |||||||
| Gross block | 0.03 | 0.03 | 0.03 | 0.03 | 0.00 | 0.11 | 0.21 |
| Net block | 0.01 | 0.01 | 0.01 | 0.03 | 0.00 | 0.11 | 0.18 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 17.85 | 3.91 | 3.91 | 2.51 | 0.00 | 0.00 | 0.00 |
| Inventories | 2.08 | 1.64 | 2.16 | 0.55 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 10.67 | 6.62 | 2.40 | 2.69 | 0.00 | 0.00 | 0.00 |
| Cash & bank balances | 0.26 | 0.02 | 0.04 | 0.09 | 2.08 | 0.00 | 0.00 |
| Loans & advances | 1.70 | 1.84 | 4.83 | 2.41 | 0.92 | 0.77 | 0.77 |
| Total current assets | 14.71 | 10.12 | 9.43 | 5.74 | 3.00 | 0.77 | 0.77 |
| Total current liabilities | 9.21 | 3.63 | 1.13 | 0.79 | 0.01 | 1.16 | 0.95 |
| Net working capital | 5.50 | 6.49 | 8.30 | 4.95 | 2.99 | (0.39) | (0.18) |
| Total assets | 27.40 | 15.59 | 12.22 | 7.48 | 2.99 | 0.10 | 0.39 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2017-18 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.02 | 0.04 | 0.09 | 2.08 | 0.00 | 0.00 | 0.57 |
| Net cash from operating activities | 1.21 | (3.25) | (3.26) | (3.87) | 2.92 | 0.00 | (0.98) |
| Net cash from investing activities | (2.00) | 0.00 | (1.40) | (2.53) | (1.55) | 0.00 | 0.42 |
| Net cash from financing activities | 1.03 | 3.23 | 4.61 | 4.40 | 0.72 | 0.00 | 0.00 |
| Net change in cash | 0.24 | (0.02) | (0.04) | (2.00) | 2.08 | 0.00 | (0.56) |
| Closing cash | 0.26 | 0.02 | 0.04 | 0.09 | 2.08 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2017-18 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -10.4% | -17.6% | +47.1% | - | - | - | - |
| EBITDA growth | -1400.0% | -43.8% | -40.7% | +2800.0% | 0.0% | - | - |
| PBT growth | - | 0.0% | -37.0% | +9998.0% | +66.7% | +97.4% | -6.4% |
| Net income growth | -1066.7% | -7.7% | -35.0% | +2100.0% | +66.7% | - | - |
| Revenue CAGR (3Y) | +2.8% | - | - | - | - | - | - |
| EBITDA CAGR (3Y) | - | - | - | - | -79.1% | -41.5% | +382.0% |
| Profitability & leverage | |||||||
| Net income margin | -10.6% | +1.0% | +0.9% | +2.0% | - | - | - |
| Return on capital employed | 0.0% | +1.4% | +1.7% | +5.2% | 0.0% | 0.0% | 0.0% |
| Return on net worth | 0.0% | +1.2% | +1.7% | +6.6% | 0.0% | 0.0% | 0.0% |
| Debt / equity | 0.23 | 0.14 | 0.29 | 0.73 | 2.17 | 0.00 | 0.00 |
| Long-term debt / equity | 0.23 | 0.14 | 0.29 | 0.73 | 2.17 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.87 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 365.33 | 407.67 | 494.67 | 672.67 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | 5.89 | 6.44 | 10.95 | 36.69 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | 1.27 | 2.71 | 5.83 | 7.50 | 0.00 | 0.00 | 0.00 |
| EPS (₹) | (0.65) | 0.12 | 0.11 | 0.68 | (0.03) | (0.14) | 0.00 |
| Dividend per share (₹) | 0.00 | 0.10 | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 12.73 | 10.09 | 10.17 | 10.25 | 9.97 | (10.18) | (7.82) |
Competitors of Bandaram Pharma Packtech
Bandaram Pharma Packtech has 3 listed competitors in our database. They include SCHOTT Poonawalla, Ideal Cures and Natural Capsules.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| schott-poonawalla.com | 1990 | Mumbai, India | 1,297 | Packaging solutions for pharmaceutical and biotech industries are provided. | ||
| idealcures.com | 1999 | Mumbai, India | Manufacturer of pharmaceutical excipients and coatings systems for solid oral dosage forms | |||
| naturalcapsules.com | 1993 | Bengaluru, India | 99 | Manufacturing and supply chain services for biopharma sector are provided. |
Detailed competitors of Bandaram Pharma Packtech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bandaram Pharma Packtech
The website of Bandaram Pharma Packtech (bandaram.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 14.2% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Bandaram Pharma Packtech (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bandaram Pharma Packtech
Complete news archive for Bandaram Pharma Packtech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bandaram Pharma Packtech
Bandaram Pharma Packtech was founded in 2022.
Bandaram Pharma Packtech is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
The primary company behind Bandaram Pharma Packtech, Bandaram Pharma Packtech Limited, reported revenue of ₹62.94 Cr for FY 2026, up 70% year on year.
Bandaram Pharma Packtech was established in 2022 and is based in Bengaluru, India. Operations focus on the pharmaceutical sector, where packaging solutions are developed and supplied. Services include design, manufacturing, and distribution of packaging materials tailored for pharmaceutical products. The company serves clients within India, emphasizing compliance with industry standards for safety and efficiency in drug containment and transport.
Bandaram Pharma Packtech's top competitors include Natural Capsules, SCHOTT Poonawalla and Ideal Cures.
Bandaram Pharma Packtech offers Investment Services.
Yes, Bandaram Pharma Packtech is publicly traded on BSE under the ticker symbol BANDARAM.
Bandaram Pharma Packtech operates through Bandaram Pharma Packtech Limited.
The legal entities of Bandaram Pharma Packtech currently have 9 directors, including Bhandaram Sathyavathi, Bhandaram Premsai Reddy, Suryaprakasa Rao Bommisetti and others.
